Pathogenesis of periodontitis: Role of cytokines in host response

Dentistry Today

Volumn 29, Issue 9, 2010, Pages 60-66

  Deo, Vikas ^a   Bhongade, M L ^a  

^a DATTA MEGHE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ALVEOLAR BONE LOSS; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PERIODONTITIS; PHYSIOLOGY; REVIEW; TOOTH PLAQUE;

ALVEOLAR BONE LOSS; CYTOKINES; DENTAL PLAQUE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MATRIX METALLOPROTEINASES; PERIODONTITIS; RECEPTORS, CYTOKINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78149265601     PISSN: 87502186     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Offenbacher S. Periodontal diseases: pathogenesis. Ann Periodontal. 1996;1:821-878.
2. Grossi SG, Zambon JJ, Ho AW, et al. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. J Periodontal. 1994;65:260-267.
3. Page RC, Kornman KS. The pathogenesis of human periodontitis: an introduction. Periodontal 2000.1997;14:9-11.
4. Graves DT, Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontal. 2003;74:391-401.
5. Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Periodontal. 2005;32(suppl 6):108-129.
6. Ejeil AL, Igondjo-Tchen S, Ghomrasseni S, et al. Expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in healthy and diseased human gingiva. J Periodontal. 2003;74:188-195.
7. Gamonal J, Acevedo A, Bascones A, et al. Levels of interleukin-1 beta, -8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. J Periodontal. 2000:71;1535-1545.
8. Hirose M, Ishihara K, Saito A, et al. Expression of cytokines and inducible nitric oxide synthase in inflamed gingival tissue. J Periodontal. 2001;72:590-597.
9. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095-2147.
10. Cullinan EB, Kwee L, Nunes P, et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol. 1998;161:5614-5620.
11. Colotta F, Sironi M, Borrè A, et al. Type II interleukin-1 receptor is not expressed in cultured endothelial cells and is not involved in endothelial cell activation. Blood. 1993:81:1347-1351.
12. Chou HH, Takashiba S, Maeda H, et al. Induction of intracellular interleukin-1 beta signals via type II interleukin-1 receptor in human gingival fibroblasts. J Dent Res. 2000:79:1683-1688.
13. Labow M, Shuster D, Zetterstrom M, et al. Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol. 1997;159:2452-2461.
14. Graves DT, Chen CP, Douville C, et al. Interleukin-1 receptor signaling rather than that of tumor necrosis factor is critical in protecting the host from the severe consequences of a polymicrobe anaerobic infection. Infect Immun. 2000;68:4746-4751.
15. Delima AJ, Karatzas S, Amar S, et al. Inflammation and tissue loss caused by periodontal pathogens is reduced by interleukin-1 antagonists. J Infect Dis. 2002;186:511-516.
16. Jandinski JJ, Stashenko P, Feder LS, et al. Localization of interleukin-1 beta in human periodontal tissue. J Periodontal. 1991;62:36-43.
17. Koide M, Suda S, Saitoh S, et al. In vivo administration of IL-1 beta accelerates silk ligature-induced alveolar bone resorption in rats. J Oral Pathol Med. 1995;24:420-434.
18. Thomson BM, Saklatvala J, Chambers TJ. Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts. J Exp Med. 1986;164:104-112.
19. Stashenko P, Dewhirst FE, Peros WJ, et al. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol. 1987;138:1464-1468.
20. Iwata T, Mitani A, Ishihara Y, et al. Actinobacillus actinomycetemcomitans Y4 capsular polysaccharide induces IL1beta mRNA expression through the JNK pathway in differentiated THP-1 cells. Clin Exp Immunol. 2005;141:261-269.
21. Delima AJ, Oates T, Assuma R, et al. Soluble antagonists to interleukin-1 (IL-1) and tumor necrosis factor (TNF) inhibits loss of tissue attachment in experimental periodontitis. J Clin Periodontal. 2001;28:233-240.
22. Kohl AC, Tatakis DN, Hansen C, et al. Effects of interleukin1, tumor necrosis factor-ß, and forskolin on tissue plasminogen activator activity in human osteoblastic osteosarcoma cells. Calcif Tissue Int. 1992;50:129-133.
23. McCauley LK, Rosol TJ, Stromberg PC, et al. Effects of interleukin-1 alpha and cyclosporin A in vivo and in vitro on bone and lymphoid tissues in mice. Toxicol Pathol. 1991;19:1-10.
24. Boyce BF, Aufdemorte TB, Garrett IR, et al. Effects of interleukin-l on bone turnover in normal mice. Endocrinology. 1989;125:1142-1150.
25. Laschinger CA, Bellows CG, Wasi S. Modulation of plasminogen activators and plasminogen activator inhibitors by TGF-ß, IL-1α and EGF in fetal rat calvaria cells at different times of culture. Bone Miner. 1991;13:23-34.
26. Evans DB, Bunning RA, Russell RG. The effects of recombinant human interleukin-1 beta on cellular proliferation and the production of prostaglandin E2, plasminogen activator, osteocalcin and alkaline phosphatase by osteoblast-like cells derived from human bone. Biochem Biophys Res Commun. 1990;166:208-216.
27. Jin CH, Miyaura C, Ishimi Y, et al. Interleukin 1 regulates the expression of osteopontin mRNA by osteoblasts. MoI Cell Endocrinol. 1990;74:221-228.
28. Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990;145:3297-3303.
29. Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Annu Rev Immunol. 1989;7:625-655.
30. Kirkwood KL, Cirelli JA, Rogers JE, et al. Novel host response therapeutic approaches to treat periodontal diseases. Periodontal 2000.2007;43:294-315.
31. Cheng X, Kinosaki M, Murali R, et al. The TNF receptor superfamily: role in immune inflammation and bone formation. Immunol Res. 2003;27(2-3):287-294.
32. Tatakis DN. Interleukin-1 and bone metabolism: a review. J Periodontal. 1993;64(suppl 5):416-431.
33. Geivelis M, Turner DW, Pederson ED, et al. Measurements of interieukin-6 in gingival crevicular fluid from adults with destructive periodontal disease. J Periodontal. 1993;64:980-983.
34. Bartold PM, Haynes DR. Interleukin-6 production by human gingival fibroblasts. J Periodontal Res. 1991;26:339-345.
35. Takahashi K, Takashiba S, Nagai A, et al. Assessment of interleukin-6 in the pathogenesis of periodontal disease. J Periodontal. 1994;65:147-153.
36. Yamazaki K, Nakajima T, Gemmell E, et al. IL-4- and IL-6-producing cells in human periodontal disease tissue. J Oral Pathol Med. 1994;23:347-353.
37. Reinhardt RA, Masada MP, Kaldahl WB, et al. Gingival fluid IL-1 and IL-6 levels in refractory periodontitis. J Clin Periodontal. 1993;20:225-231.
38. Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004;4:378-385.
39. Assuma R, Oates T, Cochran D, et al. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol. 1998;160:403-409.
40. Graves DT, Delima AJ, Assuma R, et al. Interleukln-1 and tumor necrosis factor antagonists inhibit the progression of inflammatory cell infiltration toward alveolar bone in experimental periodontitis. J Periodontal. 1998;69:1419-1425.
41. Martuscelli G, Fiorellini JP, Crohin CC, et al. The effect of interleukin-1 1 on the progression of ligature-induced periodontal disease In the beagle dog. J Periodontal. 2000;71:573-578.
42. Birkedal-Hansen H. Role of matrix metalloproteinases in human periodontal diseases. J Periodontal. 1993;64(suppl 5):474-484.
43. Reynolds JJ, Meikle MC. Mechanisms of connective tissue matrix destruction in periodontitis. Periodontal 2000. 1997;14:144-157.
44. Tervahartiala T, Pirilä E, Ceponis A, et al. The in vivo expression of the collagenolytic matrix metalloproteinases (MMP-2, -8, -13, and -14) and matrilysin (MMP-7) in adult and localized juvenile periodontitis. J Dent Res. 2000;79:1969-1977.
45. MacNaul KL, Chartrain N, Lark M, et al. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-o on stromelysin expression. J Biol Chem. 1009;265:17238-17245.
46. Cited by: Preshaw PM, Hefti AF, Jepsen S, et al. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontal. 2004;31:697-707.
47. Fullmer HM, Gibson W. Collagenolytic activity of gingivae of man. Nature. 1966;209:728-729.
48. Cited by: Ryan ME, Golub LM. Modulation of matrix metalloproteinase activities in periodontitis as a treatment strategy. Periodontal 2000. 2000;24:226-238.
49. Golub LM, Ciancio S, Ramamurthy NS, et al. Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J Periodontal Res. 1990;25:321-330.
50. Sorsa T, Uitto VJ, Suomalainen K, et al. Comparison of interstitial collagenases from human gingiva, sulcular fluid and polymorphonuclear leukocytes. J Periodontal Res. 1988;23:386-393.
51. Golub LM, Ryan M E, Williams RC. Modulation of the host response in the treatment of periodontitis. Dent Today. 1998;17:102-106,108-109.
52. Cited by: Preshaw PM, Hefti AF, Jepsen S, et al. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontal. 2004;31:697-707.
53. Mariotti A. The extracellular matrix of the periodontium: dynamic and interactive tissues. Periodontal 2000. 1993;3:39-63.
54. Uitto VJ, Airola K, Vaalamo M, et al. Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation. Am J Pathol. 1998;152:1489-1499.
55. Cited by: Preshaw PM, Hefti AF, Jepsen S, et al. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontal. 2004;31:697-707.
56. Kinane DF, Darby IB, Said S, et al. Changes in gingival crevicular fluid matrix metalloproteinase-8 levels during periodontal treatment and maintenance. J Periodontal Res. 2003;38:400-404.
57. Golub LM, Lee HM, Greenwald RA, et al. A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. Inflamm Res. 1997;46:310-319.
58. Cited by: Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Periodontal. 2005;32(suppl 6):108-129.
59. Knäuper V, López-Otin C, Smith B, et al. Biochemical characterization of human collagenase-3. J Biol Chem. 1996;271:1544-1550.
60. Cited by: Ryan ME, Golub LM. Modulation of matrix metalloproteinase activities in periodontitis as a treatment strategy. Periodontal 2000. 2000;24:226-238.
61. Hall TJ, Chambers TJ. Molecular aspects of osteoclast function. Inflamm Res. 1996;45:1-9.
62. Cited by: Ryan ME, Golub LM. Modulation of matrix metalloproteinase activities in periodontitis as a treatment strategy. Periodontal 2000. 2000;24:226-238.
63. Wucherpfennig AL, Li YP, Stetler-Stevenson WG, et al. Expression of 92 kD type IV collagenase/gelatinase B in human osteoclasts. J Bone Miner Res. 1994;9:549-556.
64. Sato T, del Carmen Ovejero M, Hou P, et al. Identification of the membrane-type matrix metalloproteinase MT1-MMP in osteoclasts. J Cell Sci. 1997;110(pt 5):589-596.
65. Cited by: Ryan ME, Golub LM. Modulation of matrix metalloproteinase activities in periodontitis as a treatment strategy. Periodontal 2000.2000;24:226-238.
66. Sodek J, Overall CM. Matrix metalloproteinases in periodontal tissue remodelling. Matrix Suppl. 1992;1:352-362.
67. Cited by: Offenbacher S. Periodontal diseases: pathogenesis. Ann Periodontal. 1996;1:821-878.
68. Sasaki T, Ramamurthy N S, Golub LM. Tetracycline administration increases collagen synthesis in osteoblasts of streptozotocin-induced diabetic rats: a quantitative autoradiographic study. Calcif Tissue Int. 1992;50:411-419.
69. Cited by: Preshaw PM, Hefti AF, Jepsen S, et al. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontal. 2004;31:697-707.
70. Gordon JM, Walker CB, Murphy JC, et al. Tetracycline: levels achievable in gingival crevice fluid and in vitro effect on subgingival organisms. Part I. Concentrations in crevicular fluid after repeated doses. J Periodontal. 1981:52:609-612.
71. Pascale D, Gordon J, Lamster I, et al. Concentration of doxycycline in human gingival fluid. J Clin Periodontal. 1986:13:841-844.
72. Golub LM, Ramamurthy NS, McNamara TF, et al. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med. 1991 ;2:297-321.
73. Burns FR, Stack MS, Gray RD, et al. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci. 1989;30:1569-1575.
74. Cited by: Preshaw PM, Hefti AF, Jepsen S, et al. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. J Clin Periodontal. 2004;31:697-707.
75. Smith GN Jr, Mickler EA, Hasty KA, et al. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum. 1999;42:1140-1146.
76. Cited by: Preshaw PM, Hefti AF, Jepsen S, et al. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontal. 2004;31:697-707.
77. Preshaw PM, Hefti AF, Jepsen S, et al. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontal. 2004;31:697-707.
78. Ryan ME, Ashley RA. How do tetracyclines work? Adv Dent Res. 1998;12:149-151.
79. Cited by: Preshaw PM, Hefti AF, Jepsen S, et al. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontal. 2004;31:697-707.
80. Nagase H, Itoh Y, Binner S. Interaction of alpha 2-macroglobulin with matrix metalloproteinases and its use for identification of their active forms. Ann N Y Acad Sci. 1994;732:294-302.
81. Cited by: Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Periodontal. 2005;32(suppl 6):108-129.
82. Rifkin BR, Vernillo AT, Golub LM. et al. Modulation of bone resorption by tetracyclines. Ann N Y Acad Sci. 1994;732:165-180.
83. Cited by: Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Periodontal. 2005;32(suppl 6):108-129.
84. Milano S, Arcoleo F, D'Agostino P, et al. Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood. Antimicrob Agents Chemother. 1997;41:117-121.
85. Cited by: Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Periodontal. 2005;32(suppl 6):108-129.
86. Caton JG, Ciancio SG, Blieden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Clin Periodontal. 2000;71:521-532.
87. Golub LM, McNamara TF, Ryan ME, et al. Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. J Clin Periodontal. 2001;28:146-156.
88. Teronen O, Heikkilä P, Konttinen YT, et al. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci. 1999;878:453-465.
89. Cited by: Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Periodontal. 2005;32(suppl 6): 108-129.